All In Biotech

Drug Trial Radar · NCT06526793

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Nov 27, 2024

Primary completion

Apr 21, 2028

Study completion Oct 21, 2032

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.

Conditions

  • B-cell Non-Hodgkin Lymphoma
  • Follicular Lymphoma (FL)
  • Large B-Cell Lymphoma (LBCL)

Interventions

  • SurovatamigDrug

    Investigational Product administered via intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR) (central review)Time frame: Module 1: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 24 months. Module 2: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 12 months.

Locations

94 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona · Withdrawn

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Jacksonville, Florida · Withdrawn

  • Research Site

    Tampa, Florida · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Iowa City, Iowa · Withdrawn

  • Research Site

    Waukee, Iowa · Recruiting

  • Research Site

    Overland Park, Kansas · Withdrawn

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    St Louis, Missouri · Withdrawn

  • Research Site

    New Brunswick, New Jersey · Withdrawn

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Charlotte, North Carolina · Recruiting

  • Research Site

    Columbus, Ohio · Recruiting

  • Research Site

    Portland, Oregon · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Withdrawn

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Austin, Texas · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    San Antonio, Texas · Recruiting

  • Research Site

    Milwaukee, Wisconsin · Recruiting

  • Research Site

    Heidelberg, Australia · Recruiting

  • Research Site

    Kogarah, Australia · Recruiting

  • Research Site

    Macquarie University, Australia · Recruiting

  • Research Site

    Nedlands, Australia · Recruiting

  • Research Site

    Porto Alegre, Brazil · Withdrawn

  • Research Site

    São Paulo, Brazil · Active not recruiting

  • Research Site

    São Paulo, Brazil · Active not recruiting

  • Research Site

    Barrie, Ontario, Canada · Withdrawn

  • Research Site

    Brampton, Ontario, Canada · Recruiting

  • Research Site

    Ottawa, Ontario, Canada · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Nanchang, China · Recruiting

  • Research Site

    Nanjing, China · Recruiting

  • Research Site

    Nantong, China · Recruiting

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.